| 前收市價 | 61.22 |
| 開市 | 61.22 |
| 買盤 | 44.35 |
| 賣出價 | 46.25 |
| 拍板 | 195.00 |
| 到期日 | 2025-12-19 |
| 今日波幅 | 61.22 - 61.22 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 1 |
ZacksPharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
ZacksAbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
